Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAIT with TF2 and 177Lu-IMP-288 in Lung Cancer
NCT01221675Phase 2Completed
- Sponsor
- Centre René Gauducheau
- Start
- Jun 2011
- Primary completion
- Apr 2016
- Modality
- Bispecific Antibodies, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 177Lu-IMP288 + TF2 in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sponsored by Centre René Gauducheau. Started Jun 2011; status: completed.
02
Drugs
177Lu-IMP288 + TF2
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01221675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01221675.